Rankia España Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
10.955 / 16.979
#87634

Re: Farmas USA

NVAX
www.DiscoverRSV.com
Edito: Framus = Lucky Luke

#87636

Re: Farmas USA

NVAX

Web simple y educativa... bien, bien.

#87637

Re: Farmas USA

Sorprendentemente mi orden de NVAX no se ha ejecutado ....lo bueno : mañana las cogere más bajas , lo malo: mañana no quería ni mirar , y ahora me obliga a estar atento....🤔

#87638

Re: Farmas USA

Hasta 4'62 hemos llegado en el AH... Ánimo, un revés nada más, otro claro.

#87640

Re: Farmas USA

CNAT +27% AH
Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
- Continued Directional Improvements in Key Measures of Liver Function after Six Months -

- First Drug to Demonstrate Liver Function Benefit in Patients with NASH Cirrhosis -

- Conference Call and Webcast Presentation at 8:00 a.m. ET on Thursday, May 5 -

SAN DIEGO, May 04, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced positive top-line results from the three-month, open-label second stage of the company's multicenter Phase 2 clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, in patients with liver cirrhosis. Top-line results from the three-month placebo-controlled first stage of the trial were released in January. In the second stage, patients on emricasan in the first stage continued treatment for another three months, and patients on placebo in the first stage switched over to emricasan for three months.

Guía Básica
Brokers destacados